Safety and Efficacy of Apixaban vs Warfarin in Patients With Stage 4 and 5 Chronic Kidney Disease: A Systematic Review

Safety and Efficacy of Apixaban vs Warfarin in Patients With Stage 4 and 5 Chronic Kidney Disease: A Systematic Review

Warfarin has been an anticoagulant of choice in patients with advanced Chronic Kidney Diseases (CKD) at stages 4 and 5 for decades, but with the advent of Novel Oral Anticoagulants (NOACs), there has been a sharp rise in their prescriptions. Among all NOACS, apixaban is the least reliant on kidney f...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Curēus (Palo Alto, CA) CA), 2022-10, Vol.14 (10), p.e30230-e30230
Hauptverfasser: Fatima, Hameeda, Nwankwo, Ijeoma, Anam, Mahvish, Maharjan, Shrinkhala, Amjad, Zainab, Abaza, Abdelrahman, Vasavada, Advait M, Sadhu, Akhil, Valencia, Carla, Khan, Safeera
Format: Artikel
Sprache:eng
Schlagworte:
Anticoagulants
Bias
Bibliographic literature
Cardiac arrhythmia
Cardiology
Clinical trials
Cohort analysis
Creatinine
FDA approval
Hemodialysis
Internal Medicine
Kidney diseases
Nephrology
Stroke
Systematic review
Thromboembolism
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Warfarin has been an anticoagulant of choice in patients with advanced Chronic Kidney Diseases (CKD) at stages 4 and 5 for decades, but with the advent of Novel Oral Anticoagulants (NOACs), there has been a sharp rise in their prescriptions. Among all NOACS, apixaban is the least reliant on kidney function and is a very popular choice for this patient population. However, being utilized extensively, most of the landmark trials evaluating the safety and efficacy of apixaban excluded patients with Creatinine Clearance (CrCl)
ISSN:2168-8184
2168-8184
DOI:10.7759/cureus.30230